You are here » Home » Companies » Company Overview » Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd.

BSE: 506879 Sector: Health care
NSE: GUJTHEMIS ISIN Code: INE942C01029
BSE 12:37 | 30 Nov 499.45 4.95
(1.00%)
OPEN

493.00

HIGH

523.00

LOW

493.00

NSE 05:30 | 01 Jan Gujarat Themis Biosyn Ltd
OPEN 493.00
PREVIOUS CLOSE 494.50
VOLUME 6129
52-Week high 692.00
52-Week low 196.00
P/E 18.16
Mkt Cap.(Rs cr) 725
Buy Price 493.30
Buy Qty 8.00
Sell Price 496.00
Sell Qty 100.00
OPEN 493.00
CLOSE 494.50
VOLUME 6129
52-Week high 692.00
52-Week low 196.00
P/E 18.16
Mkt Cap.(Rs cr) 725
Buy Price 493.30
Buy Qty 8.00
Sell Price 496.00
Sell Qty 100.00

Gujarat Themis Biosyn Ltd. (GUJTHEMIS) - Chairman Speech

Company chairman speech

Dear Stakeholders

I would like to start this letter with a sincere thanks to all my stakeholderspartners and employees who continue to stand with us and support us in our journey. Ourmission has always been to provide reliable safe and affordable products thus helpingpeople to live healthier lives.

This year marks a year of transformation for our Company which has resulted in asignificant improvement in the financial performance of the Company. This was possibleonly because of the immense contribution made by its promoter viz. Themis MedicareLimited (Themis) who have done a lot of study in the market identified the customerconducted negotiations and ensured that business is channelized from them to the Company.Besides Themis has also provided managerial inputs and technical support by way oftechnology and has been a constant source of support to the Company till date.

I on behalf of myself and my collegues on the Board wish to place on record ourrecognition of the contribution and our deep appreciation and gratitude to Themis for thesame.

We have continued to live up to our dedication and commitment towards servicing themarket needs. We commercialised production of Rifamycin O in September 2019 on the basisof technical input provided by Themis.

This second milestone that we achieved carves a new and exciting path to much betterfuture for our Company. So far we have been manufacturing our products through contractmanufacturing. We have now changed our business model to manufacture and sales. Ourlong-standing reputation in the pharma industry has helped to create increased demand ofour products. This has led to increased growth in our top line and profitability. We havebeen able to move from contract manufacturing to manufacture and sales model only due tocontinued efforts of our team and support from Themis. We are confident that our currenttalent pool not only sincere and dedicated but also promising and will help our Companyoutperform our previous performances and enable us to translate our great vision intoreality.

Moving to FY20 financials I would like to share that our Company recorded an increasein sales of 107.37 % from Rs. 41.05 cr in FY19 to Rs. 85.12 cr in FY20. The full yearperformance can be hugely contributed to the change in our business model andmanufacturing of new products. The EBIDTA also shows a drastic improvement of 334.21% toRs 31.84 cr due to increase in revenue. The Company registered 269% increase in netprofit from Rs. 6.41 cr in FY19 to Rs. 23.67 cr in FY20.

I would like to take this opportunity to thank each member of the GTBL family. I wouldalso like to thank our Customers Creditors Banks Financial Institutions and otherStakeholders. Their faith in us and their continued support makes it easier for us tostrive and excel.

Yours sincerely Sd/-

Dr. Dinesh S. Patel

Chairman

.